Estudos sobre reposição hormonal

Que estudos ainda precisam ser feitos sobre reposição hormonal?

Permanecem dúvidas sobre os efeitos adversos à saúde associados ao uso de estrogênio sozinho em mulheres pós-menopausa. Questões adicionais não resolvidas são: se as diferentes formas de hormônios, menores doses, hormônios diferentes, ou diferentes vias de administração são mais seguros ou eficientes; se os riscos e/ou benefícios persistem depois que a mulher para de tomar os hormônios; se a mulher poderia ser capaz de tomar hormônios com segurança por um curto período de tempo; e se certos subgrupos de mulheres poderiam ter um risco maior ou menor do que a população geral.

O WHI (Women's Health Initiative) continua a fazer pesquisas que têm como foco os caminhos para prevenir doença cardíaca, câncer de mama e colorretal, e frutas, vegetais e grãos na prevenção de câncer de mama e colorretal, doença cardíaca, assim como o efeito dos suplementos alimentares de cálcio e vitamina D sobre a prevenção de fraturas relacionadas à osteoporose.

Muitos estudos estão sendo feitos para avaliar a associação ente a reposição hormonal na menopausa e a ocorrência de câncer colorretal (45). Outros projetos de pesquisa estão descritos em vários sites governamentais (46, 47).

PUBLICIDADE

Perguntas e respostas sobre reposição hormonal menopausa

Gostou desse artigo? Então você pode recomendá-lo com o Google +1:

Créditos:
National Cancer Institute
Tradução: © Hélio Augusto Ferreira Fontes

Referências

  1. Brett KM, Madans JH. Use of menopausal hormone replacement therapy: Estimates from a nationally representative cohort study. American Journal of Epidemiology 1997;145(6):536-545.

  2. Writing Group for the Women's Health Initiative. Risks and benefits of combined estrogen and progestin in healthy menopausal women: Principal results from the Women's Health Initiative randomized controlled trial. The Journal of the American Medical Association 2002;288:321-333.

  3. Shumaker, SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Journal of the American Medical Association 2003;289:2651-2662.

  4. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Journal of the American Medical Association 2003;289:2663-2672.

  5. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. The New England Journal of Medicine 2003;348:1839-1854.

  6. Tavani A, La Vecchia C. The adverse effects of hormone replacement therapy. Drugs & Aging 1999;14(5):347-357.

  7. Pike MC, Peters RK, Cozen W, et al. Estrogen-progestin replacement therapy and endometrial cancer. Journal of the National Cancer Institute 1997;89:1110-1116.

  8. Beresford S, Weiss N, Voigt L, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in menopausal women. Lancet 1997;349:458-461.

  9. Newcomb PA and Trentham-Dietz A. Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States). Cancer Causes & Control 2003;14(2):195-201.

  10. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: The Women's Health Initiative randomized trial. The Journal of the American Medical Association 2003;290(13):1739-1748.

  11. Chlebowski RT, Hendrix SL, Langer RD, et al. Estrogen plus progestin influence on breast cancer and mammography in healthy postmenopausal women in the Women's Health Initiative randomized trial. The Journal of the American Medical Association 2003;289:3243.

  12. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy. Lancet 1997;350:1047-1059.

  13. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.

  14. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effective hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. Journal of the National Cancer Institute 2000;92:328-332.

  15. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. The Journal of the American Medical Association 2000;283(4):485-491.

  16. Lacey JV, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer in a prospective study. The Journal of the American Medical Association 2002;288:334-341.

  17. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of U.S. women. The Journal of the American Medical Association 2001;285(11):1460-1465.

  18. Riman T, Dickman PW, Nilsson S, et al. Hormone replacement therapy and the risk of invasive ovarian cancer in Swedish women. Journal of the National Cancer Institute 2002;94:497-504.

  19. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. The New England Journal of Medicine 2003;349:523-534.

  20. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. The Journal of the American Medical Association 2002;288:49-57.

  21. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. The New England Journal of Medicine 2003;349:535-545.

  22. Rosano GM, Painina G. Cardiovascular pharmacology of hormone replacement therapy. Drugs & Aging 1999;15(3):219-234.

  23. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Journal of the American Medical Association 2003;290(13):1729-1738.

  24. Reid IR. Pharmacological management of osteoporosis in menopausal women: A comparative review. Drugs & Aging 1999;15(5):349-363.

  25. Rosenberg S, Vandromme J, Ayata NB, Filippidis M, Kroll M. Osteoporosis management. International Journal of Fertility and Women's Medicine 1999;44(5):241-249.

  26. Hlatky MA, Boothroyd D, Vittinghoff E, et al. Quality-of-life and depressive symptoms in menopausal women after receiving hormone therapy: Results from the Heart and Estrogen/Progestin Replacement Study trial. The Journal of the American Medical Association 2002;287:591-596.

  27. Grady D, Wenger NK, Herrington D, et al. Menopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study. Annals of Internal Medicine 2000;132:689-696.

  28. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. The Journal of the American Medical Association 2002; 288:58-66.

  29. Castellsague J, Perez Gutthann S, Garcia Rodriguez LA. Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism: A review. Drug Safety 1998;18(2):117-123.

  30. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women. The Journal of the American Medical Association 2003;289:2673-2684.

  31. Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2001;103:638.

  32. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. The New England Journal of Medicine 2001;345:1243-1249.

  33. Simon JA, Hunninghake DB, Agarwal SK, et al. Effect of estrogen plus progestin on risk for biliary tract surgery in menopausal women with coronary artery disease. The Heart and Estrogen/Progestin Replacement Study. Annals of Internal Medicine 2001;135:493-501.

  34. Kakar F, Weiss NS, Strite SA. Noncontraceptive estrogen use and risk of gallstone disease in women. American Journal of Public Health 1988;78:564.

  35. Seifert M, Galid A, Kubista E. Estrogen replacement therapy in women with a history of breast cancer. Maturitas 1999;32(2):63-68.

  36. Burger CW, van Leeuwen FE, Scheele F, Kenemans P. Hormone replacement therapy in women treated for gynaecological malignancy. Maturitas 1999;32(2):69-76.

  37. O'Meara ES, Rossing MA, Daling JR, et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. Journal of the National Cancer Institute 2001;93:754-762.

  38. Schairer C, Gail M, Byrne C, et al. Estrogen replacement therapy and breast cancer survival in a large screening study. Journal of the National Cancer Institute 1999;91:264-270.

  39. Baker VL. Alternatives to oral estrogen replacement. Obstetrics and Gynecology Clinics of North America 1994;21(2):271-297.

  40. Sturdee DW. Current hormone replacement therapy: What are the shortcomings? Advances in delivery. International Journal of Clinical Practice 1999;53(6):468-472.

  41. Ansbacher R. The pharmokinetics and efficacy of different estrogens are not equivalent. American Journal of Obstetrics and Gynecology 2001;184:255-263.

  42. Keller C, Fullerton J, Mobley C. Supplemental and complementary alternatives to hormone replacement therapy. Journal of the American Academy of Nurse Practitioners 1999;11(5):187-198.

  43. (No authors listed) Raloxifene approval ushers in new drug class for osteoporosis. Estrogen-receptor effects vary by tissue type. American Journal of Health-System Pharmacy 1998;55(2):104.

  44. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials 1998;19(1):61-109.

  45. Hormone replacement therapy and large bowel cancer risk, National Cancer Institute Research Portfolio, Project 36118; https://researchportfolio.cancer.gov.  

  46. https://researchportfolio.cancer.gov 

  47. https://clinicaltrials.gov 

VoltarVoltar a mulher corredora

Use essa ferramenta abaixo pesquisar nesse site:  

Use a busca abaixo para encontrar o que deseja em mais de 5 mil páginas sobre esporte, saúde e bem-estar:

© 1999-2018 Helio A. F. Fontes
Utilização de material original do site
 Copacabana Runners - Atletismo e Maratonas